NGM Biopharmaceuticals: Funding, Investors & Team (Sep 2026)
NGM Biopharmaceuticals is a privately-owned company dedicated to finding groundbreaking medicines that significantly enhance human health. Using new clinical and genetic findings, the company has developed unique methods to uncover potential treatments for metabolic and heart conditions. Their primary focus is on the gastrointestinal endocrine system, aiming to discover new factors related to type 2 diabetes and its resolution in patients who have had gastric bypass surgery.
NGM Biopharmaceuticals has raised $122M across 1 funding round on record, the most recent a Series A of $122M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NGM Biopharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jul 2024.
NGM Biopharmaceuticals Funding Rounds
NGM Biopharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
NGM Biopharmaceuticals Funding Compared to Other Biotechnology Startups
NGM Biopharmaceuticals' latest round of $122M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NGM Biopharmaceuticals in Biotechnology and South San Francisco
Companies Similar to NGM Biopharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
NGM Biopharmaceuticals Funding FAQs
What does NGM Biopharmaceuticals do?
NGM Biopharmaceuticals is a privately-owned company dedicated to finding groundbreaking medicines that significantly enhance human health. Using new clinical and genetic findings, the company has developed unique methods to uncover potential treatments for metabolic and heart conditions. Their primary focus is on the gastrointestinal endocrine system, aiming to discover new factors related to type 2 diabetes and its resolution in patients who have had gastric bypass surgery.
How much funding has NGM Biopharmaceuticals raised?
NGM Biopharmaceuticals has raised $122M across 1 round on record. The most recent is a Series A of $122M announced in Jul 2024.
When did NGM Biopharmaceuticals last raise funding?
NGM Biopharmaceuticals' most recent funding round on record is a Series A of $122M, announced in Jul 2024.
Who founded NGM Biopharmaceuticals?
FundedIQ lists Kamala Chaubey (Founder) at NGM Biopharmaceuticals.
Where is NGM Biopharmaceuticals headquartered?
NGM Biopharmaceuticals is based in South San Francisco, California, United States.
How many employees does NGM Biopharmaceuticals have?
NGM Biopharmaceuticals is in the 101-250 employee band.
How does NGM Biopharmaceuticals' funding compare to other Biotechnology startups?
NGM Biopharmaceuticals' latest round of $122M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's NGM Biopharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NGM Biopharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.